Envoy Medical Q3 revenue rises to $66 thousand; loss to common narrows to $5.2 million
Envoy Medical reported third-quarter 2026 results for the quarter ended September 30, 2026. Net revenue rose to $66 thousand from $42 thousand, and the net loss attributable to common stockholders narrowed to $5.2 million, or $0.50 per share, from $7.7 million, or $3.55 per share, a year earlier. The company also reported cash of $14.6 million at quarter end, up from $3.7 million at December 31, 2025, and said its pivotal trial of the fully implanted Acclaim cochlear implant has reached the six-month follow-up milestone for all 56 patients.
Key points
- Net revenue was $66 thousand for the quarter, compared with $42 thousand a year earlier.
- Net loss attributable to common stockholders was $5.2 million, or $0.50 per share, versus $7.7 million, or $3.55 per share, in the prior-year quarter.
- R&D expenses rose to $3.1 million from $2.7 million, mainly reflecting clinical trial follow-up activity.
- On October 6, 2026, the Atlas Merchant Capital litigation was dismissed with prejudice, with no payment by the company.
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.